Friday Pop Quiz 1/24/2025
In 2022 the FDA approved a medication for the treatment of the condition dipicted in the image. It inhibits the same enzymes as which of the following?
A. Ruxolitinib
B. Abrocitinib
C. Apremilast
D. Adalimumab
E. Tofacitinib
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
…
In 2022 the FDA approved a medication for the treatment of the condition dipicted in the image. It inhibits the same enzymes as which of the following?
A. Ruxolitinib
B. Abrocitinib
C. Apremilast
D. Adalimumab
E. Tofacitinib
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
With a special focus on aesthetic treatments, check out highlights from the September issue of the Journal of Drugs in Dermatology (JDD) straight from the Editor’s desk:
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for t … 
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l … 
INSIDER recently posted an article on oral minoxidil for hair loss as a result of media coverage in The New York Times. Which hair loss patients make good candidates for oral minoxidil? How should a dermatologist determine the best dosage for their patients?
For expert advice, I reached out to Shilpi Khetarpal, MD, FAAD, director of cosmetic dermatology and lasers at the Cleveland Clinic.
… 
Dr. Friedman, jack of many trades, Professor and Interim Chair of Dermatology at George Washington University provided an excellent overview of ways to achieve victory over atopic dermatitis (AD). This expert discussion took place during the ODAC Inflammatory Diseases Symposium on December 3, 2020.
How could we possibly cover atopic dermatitis in 20 minutes? Well, Dr. Friedman skillfully led us …